Ocugen Inc
NASDAQ:OCGN
| Market Cap (Intraday) | 317.03M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $1.22 |
| 50-Day MA | $1.46 |
| 200-Day MA | $1.15 |
Ocugen Inc Stock, NASDAQ:OCGN
11 Great Valley Parkway, Suite 160, Malvern, Pennsylvania 19355
United States of America
Phone: +1.484.328.4701
Number of Employees: 65
Description
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.